The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

Researchers proposed changing the recommendations for universal driving restrictions after CAR T-cell infusion.

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

In this interview, Christian Chabannon and Edoardo Campodonico discuss the potential of CAR-T cell therapy holds in treating ...

A team has identified a previously unknown phase of the immune response. The results challenge long-standing assumptions about the process called 'T-cell priming'. These new insights have significant ...

After 3.5 years of follow-up, there was a 98% rate of minimal residual disease, and 9 patients were still in complete remission.

Dean Berhaupt has become the first patient to receive CAR T-cell therapy in Albany, marking a significant milestone for ...

Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

Explore the impact of functional respiratory tests on outcomes in anti-CD19 CAR T-cell therapy, presented at EBMT 2025.

The research groups led by Wolfgang Kastenmüller and Georg Gasteiger employed innovative microscopy techniques to observe how ...

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring.